Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Northwest Biotherapeutics, Inc. NWBO OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
26/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Northwest Biotherapeutics, Inc. (NWBO) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is neutral — 1 Hold.

NWBO Analyst Ratings

Hold
1
Ratings
1 Hold
Based on 1 analysts giving stock ratings to Northwest Biotherapeutics, Inc. in the past 3 months
Rating breakdown
Hold
1 100%
0%
Buy
0 analysts
100%
Hold
1 analysts
0%
Sell
0 analysts

People Also View

CLDX
CLDX
Celldex Therapeutics, Inc.
$33.33
+2.27%
 CVM
CVM
CEL-SCI Corporation
$4.36
+8.46%
 ADXS
ADXS
Advaxis, Inc.
$0.60
+0.00%
 IMUC
IMUC
ImmunoCellular Therapeutics, Ltd.
$0.12
-8.41%
 ONCS
ONCS
OncoSec Medical Incorporated
$0.28
+31.87%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message